�����鶹

Image

Biotechnology companies like those started by �����鶹’s  continue to develop new ways to discover and engineer antibodies for use as therapeutics, The Scientist reports.

Gerngross, the associate provost of Entrepreneurship & Technology Transfer and a professor of bioengineering at , has started several biotech companies, including Adimab, the article notes. “It’s a great time to be in this space,” Gerngross tells The Scientist.

The first of Adimab’s antibody therapies is headed into clinical trials, the article notes. “Gerngross’s success is not only a tribute to his company’s technology, but an indication of the industry’s continued thirst for new antibodies,” the magazine writes.

 

, published 9/1/13 by The Scientist.